TD Asset Management Inc Has $69.92 Million Stake in Bristol Myers Squibb Company $BMY

TD Asset Management Inc trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,296,167 shares of the biopharmaceutical company’s stock after selling 72,677 shares during the period. TD Asset Management Inc’s holdings in Bristol Myers Squibb were worth $69,915,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares in the last quarter. EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the 4th quarter worth $32,000. KERR FINANCIAL PLANNING Corp acquired a new position in Bristol Myers Squibb during the 3rd quarter worth $35,000. Finally, Garner Asset Management Corp acquired a new position in Bristol Myers Squibb during the 4th quarter worth $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the topic of several research reports. Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. HSBC upped their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $61.31.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for previously untreated stage III or IV classical Hodgkin lymphoma in the EU, which could expand Bristol Myers Squibb’s reach in a key oncology market. How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
• Positive Sentiment: At ASCO 2026, Bristol Myers Squibb highlighted promising late-stage cancer data, including Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and survival data for izalontamab brengitecan, reinforcing the company’s pipeline momentum. Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
• Positive Sentiment: Arcus Biosciences and Bristol Myers Squibb expanded their kidney cancer collaboration to advance casdatifan combinations in ccRCC, giving BMY another clinical-development opportunity in oncology. Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
• Neutral Sentiment: Several articles noted that Bristol Myers Squibb remains attractive to value and dividend-focused investors, with commentary pointing to its yield and dividend durability rather than a major near-term catalyst. Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
• Neutral Sentiment: Bristol Myers Squibb also drew attention from an options-volume report, suggesting heightened trading interest, though the item did not point to a specific fundamental driver. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $57.24 on Friday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The firm has a market capitalization of $116.88 billion, a price-to-earnings ratio of 16.08, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm has a fifty day moving average of $58.10 and a 200-day moving average of $56.52.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.